Summary & Overview
HCPCS J1560: Intramuscular Gamma Globulin Injection Over 10 cc
HCPCS Level II code J1560 denotes an intramuscular administration of gamma globulin in volumes greater than 10 cc. This code captures a specific formulation and route of immunoglobulin therapy that is distinct from intravenous preparations and smaller-volume intramuscular injections. It matters nationally because immunoglobulin therapies are used in a range of immune deficiency and autoimmune indications, and clarity in coding supports accurate billing, coverage determinations, and utilization tracking.
Key payers discussed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of payer coverage patterns, common billing modifiers applied to injectable therapies, and the clinical administration context for intramuscular gamma globulin. The publication summarizes national benchmarks for coding frequency and allowed services where available, highlights relevant policy considerations affecting reimbursement and prior authorization, and provides clinical context to distinguish J1560 from other immunoglobulin administration codes.
The content is organized to help billing managers, compliance officers, and policy analysts understand how J1560 is used, what typical sites of service are, and what to expect from major payers. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J1560 describes an injection of gamma globulin administered intramuscularly in volumes greater than 10 cc. The service is an injectable immunoglobulin administration intended for intramuscular delivery.
Service type: Injection / Therapeutic Administration
Typical site of service: Clinic, physician office, outpatient infusion center, or other outpatient setting where intramuscular injections are performed.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to an outpatient infusion clinic or primary care office for administration of intramuscular gamma globulin preparations when larger-volume IM immunoglobulin is required (volume >10 cc). The patient may have a history of immunodeficiency, passive immunization need after exposure (for example, hepatitis A or rabies post‑exposure prophylaxis in select cases), or failure/intolerance of intravenous administration. Workflow begins with clinician evaluation and documentation of indication and consent, verification of immunoglobulin product and lot, nursing preparation and dose calculation, review of allergies and prior adverse reactions, administration via deep intramuscular injection (usually into the gluteus maximus or vastus lateralis depending on volume and patient age), observation for immediate adverse reaction (15–30 minutes), documentation of lot number and injection site, and coding/billing using J1560 for the injected product when the administered volume exceeds 10 cc per the HCPCS descriptor. Typical site of service is outpatient clinic, physician office, or ambulatory infusion center; alternate sites include emergency department when given for post‑exposure prophylaxis.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no special claims modifier applies and payer requires a placeholder; rarely reported explicitly to payers that do not accept . |